Related Experiment Video

Updated: Jul 13, 2026

Real-Time Polymerase Chain Reaction-Based Detection and Quantification of Hepatitis B Virus DNA
04:11

Real-Time Polymerase Chain Reaction-Based Detection and Quantification of Hepatitis B Virus DNA

Published on: December 15, 2023

[Relationship between serum HBV DNA levels and hepatic fibrosis markers in chronic hepatitis B]

Zhong Dong1, Hong Shen, Fu-kui Zhang

  • 1Liver Research Center, Beijing Friendship Hospital, Capital University of Medical Sciences, Beijing, 100050 China.

Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi = Zhonghua Shiyan He Linchuang Bingduxue Zazhi = Chinese Journal of Experimental and Clinical Virology
|July 27, 2007
PubMed

Insights

In chronic hepatitis B, serum HBV DNA levels showed no significant relationship with hepatic fibrosis markers. Early cirrhosis patients had higher fibrosis markers and lower HBV DNA levels than non-cirrhotic individuals.

Area of Science:

  • Hepatology
  • Virology
  • Biochemistry

Context:

  • Chronic hepatitis B (CHB) is a significant global health concern.
  • Hepatic fibrosis is a key determinant of liver disease progression in CHB.
  • Accurate assessment of fibrosis is crucial for patient management.

Purpose:

  • To investigate the correlation between serum hepatitis B virus (HBV) DNA levels and established hepatic fibrosis markers in patients with CHB.
  • To compare HBV DNA levels and fibrosis markers between cirrhotic and non-cirrhotic CHB patients.

Summary:

  • A study of 157 CHB patients, including 49 with early cirrhosis, analyzed serum HBV DNA levels and fibrosis markers (hyaluronic acid, laminin, P III P, IV-C).
  • Results indicated no significant relationship between serum HBV DNA levels and hepatic fibrosis markers in the overall CHB cohort.
  • Conversely, patients with early cirrhosis exhibited significantly higher fibrosis markers and lower HBV DNA levels compared to non-cirrhotic patients.

Impact:

  • This study suggests that serum HBV DNA levels may not be a reliable indicator of hepatic fibrosis severity in CHB.
  • Findings highlight the complex interplay between viral load and fibrogenesis in CHB.
  • Further research may explore alternative non-invasive biomarkers for fibrosis staging in CHB.
Abstract

More Related Videos

"Liver-on-a-Chip" Cultures of Primary Hepatocytes and Kupffer Cells for Hepatitis B Virus Infection10:25

"Liver-on-a-Chip" Cultures of Primary Hepatocytes and Kupffer Cells for Hepatitis B Virus Infection

Published on: February 19, 2019

Related Concept Videos

Hepatitis01:25

Hepatitis

Hepatitis is an inflammatory condition of the liver most commonly caused by hepatotropic viruses (A–E), though non-infectious causes such as alcohol and drugs also exist.Hepatitis AHepatitis A virus (HAV) is a non-enveloped RNA virus of the Picornaviridae family. It is primarily transmitted via the fecal-oral route, typically through ingestion of contaminated food or water. After ingestion, HAV enters the bloodstream through the oropharynx or intestinal epithelium and reaches the liver. The...
Cirrhosis I: Introduction01:23

Cirrhosis I: Introduction

Cirrhosis is a chronic, irreversible liver disease characterized by the widespread replacement of healthy liver tissue with fibrotic scar tissue and the formation of regenerative nodules.Etiology of cirrhosisCirrhosis results from sustained liver injury that triggers progressive fibrosis and structural remodeling. The underlying causes are diverse, encompassing common and less frequent clinical conditions. Regardless of the origin, all causes lead to chronic inflammation, hepatocyte loss, and...
Cirrhosis II: Pathophysiology01:24

Cirrhosis II: Pathophysiology

Cirrhosis is a progressive chronic liver injury caused by prolonged inflammation, excessive fibrotic remodeling, and impaired regeneration. Over time, repeated hepatic insults disrupt the liver’s architecture and function, leading to reduced blood flow, impaired bile drainage, and diminished metabolic capacity.Pathophysiology of cirrhosisCirrhosis arises from three main responses to chronic liver damage: inflammation, immune activation, and hepatocyte death. These processes lead to structural...
Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow01:26

Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow

Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug binding...
Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test01:22

Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test

In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess the...
Ultrasound II: Endoscopic Ultrasound and FibroScan01:25

Ultrasound II: Endoscopic Ultrasound and FibroScan

Endoscopic Ultrasound (EUS) and FibroScan are valuable diagnostic tools in gastroenterology and hepatology, each with specific applications and techniques.
Endoscopic Ultrasound (EUS):